Hara K, Kubota N, Tobe K, Terauchi Y, Miki H, Komeda K, Tamemoto H, Yamauchi T, Hagura R, Ito C, Akanuma Y, Kadowaki T
Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan.
Br J Nutr. 2000 Dec;84 Suppl 2:S235-9. doi: 10.1079/096582197388608.
The biological role of peroxisome proliferator-activated receptor gamma (PPARgamma) was investigated by gene targeting and case-control study of the Pro12Ala PPARgamma2 polymorphism. Homozygous PPARgamma-deficient embryos died at 10.5-11.5 days post conception (dpc) due to placental dysfunction. Heterozygous PPARgamma-deficient mice were protected from the development of insulin resistance due to adipocyte hypertrophy under a high-fat diet, whose phenotypes were abrogated by PPARgamma agonist treatment. Heterozygous PPARgamma-deficient mice showed overexpression and hypersecretion of leptin despite the smaller size of adipocytes and decreased fat mass, which may explain these phenotypes at least in part. This study reveals a hitherto unpredicted role for PPARgamma in high-fat diet-induced obesity due to adipocyte hypertrophy and insulin resistance, which requires both alleles of PPARgamma. A Pro12Ala polymorphism has been detected in the human PPARgamma2 gene. Since this amino acid substitution may cause a reduction in the transcriptional activity of PPARgamma, this polymorphism may be associated with decreased insulin resistance and decreased risk of type 2 diabetes. To investigate this hypothesis, we performed a case-control study of the Pro12Ala PPARgamma2 polymorphism. In an obese group, subjects with Ala12 were more insulin sensitive than those without. The frequency of Ala12 was significantly lower in the diabetic group, suggesting that this polymorphism protects against type 2 diabetes. These results revealed that in both mice and humans, PPARgamma is a thrifty gene mediating type 2 diabetes.
通过基因靶向以及对Pro12Ala PPARγ2多态性的病例对照研究,对过氧化物酶体增殖物激活受体γ(PPARγ)的生物学作用进行了研究。纯合PPARγ缺陷胚胎在受孕后10.5 - 11.5天(dpc)因胎盘功能障碍死亡。杂合PPARγ缺陷小鼠在高脂饮食下因脂肪细胞肥大而免受胰岛素抵抗的发展,其表型通过PPARγ激动剂治疗得以消除。杂合PPARγ缺陷小鼠尽管脂肪细胞较小且脂肪量减少,但仍表现出瘦素的过度表达和分泌过多,这可能至少部分解释了这些表型。本研究揭示了PPARγ在高脂饮食诱导的因脂肪细胞肥大和胰岛素抵抗导致的肥胖中迄今未被预测的作用,这需要PPARγ的两个等位基因。在人类PPARγ2基因中检测到了Pro12Ala多态性。由于这种氨基酸替代可能导致PPARγ转录活性降低,这种多态性可能与胰岛素抵抗降低和2型糖尿病风险降低有关。为了研究这一假设,我们对Pro12Ala PPARγ2多态性进行了病例对照研究。在肥胖组中,携带Ala12的受试者比未携带的受试者胰岛素敏感性更高。糖尿病组中Ala12的频率显著更低,表明这种多态性可预防2型糖尿病。这些结果表明,在小鼠和人类中,PPARγ都是介导2型糖尿病的节俭基因。